Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy ; volume:6 ; number:1 ; day:1 ; month:6 ; year:2011 ; pages:1-8 ; date:12.2011
Orphanet journal of rare diseases ; 6, Heft 1 (1.6.2011), 1-8, 12.2011
- Urheber
-
Güngör, Deniz
- Beteiligte Personen und Organisationen
-
de Vries, Juna M.
Hop, Wim CJ
Reuser, Arnold JJ
van Doorn, Pieter A.
van der Ploeg, Ans T.
Hagemans, Marloes LC
SpringerLink (Online service)
- DOI
-
10.1186/1750-1172-6-34
- URN
-
urn:nbn:de:1111-2016050120073
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Güngör, Deniz
- de Vries, Juna M.
- Hop, Wim CJ
- Reuser, Arnold JJ
- van Doorn, Pieter A.
- van der Ploeg, Ans T.
- Hagemans, Marloes LC
- SpringerLink (Online service)
Ähnliche Objekte (12)
Enzyme replacement therapy and fatigue in adults with Pompe disease
Enzyme replacement therapy (ERT) in pompe disease
Impact of enzyme replacement therapy on survival in adults with Pompe disease
Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy
Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study
Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease
The impact of interrupting enzyme replacement therapy in late-onset Pompe disease
Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy
Enzyme replacement therapy and fatigue in adults with Pompe disease
Enzyme replacement therapy (ERT) in pompe disease
Impact of enzyme replacement therapy on survival in adults with Pompe disease
Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy
Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study
Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease
The impact of interrupting enzyme replacement therapy in late-onset Pompe disease
Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy
Enzyme replacement therapy and fatigue in adults with Pompe disease
Enzyme replacement therapy (ERT) in pompe disease
Impact of enzyme replacement therapy on survival in adults with Pompe disease
Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy
Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study
Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease
The impact of interrupting enzyme replacement therapy in late-onset Pompe disease